Identification of a novel type of small molecule inhibitor against HIV-1 |
Kim, Byung Soo
(Avixgen Inc.)
Park, Jung Ae (Avixgen Inc.) Kim, Min-Jung (Avixgen Inc.) Kim, Seon Hee (National Research Laboratory of Molecular Virology, Department of Pathology, School of Medicine, The Catholic University of Korea) Yu, Kyung Lee (National Research Laboratory of Molecular Virology, Department of Pathology, School of Medicine, The Catholic University of Korea) You, Ji Chang (Avixgen Inc.) |
1 | Hayashi S, Phadtare S, Zemlicka J, Matsukura M, Mitsuya H and Broder S (1988) Adenallene and cytallene: acyclic- nucleoside analogues that inhibit replication and cytopathic effect of human immunodeficiency virus in vitro. Proc Natl Acad Sci U S A 85, 6127-6131 DOI ScienceOn |
2 | Dubé M, Bego MG, Paquay C and Cohen ÉA (2010) Modulation of HIV-1 host interaction: role of the Vpu accessory protein. Retrovirology 7, 144 DOI |
3 | Li ZY, Zhan P and Liu XY (2010) Progression in the study of HIV-1 Vif and related inhibitors. Yao Xue Xue Bao 45, 684-693 |
4 | Kwon HS, Park JA, Kim JH and You JC (2012) Identification of anti-HIV and anti-reverse transcriptase activity from Tetracera scandens. BMB Rep 45, 165-170 DOI ScienceOn |
5 | Forshey BM, von Schwedler U, Sundquist WI and Aiken C (2002) Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. J Virol 76, 5667-5677 DOI |
6 | Srivastava P, Schito M, Fattah RJ et al (2004) Optimization of unique, uncharged thioesters as inhibitors of HIV replication. Bioorg Med Chem 12, 6437-6450 DOI ScienceOn |
7 | Ong EB, Watanabe N, Saito A et al (2011) Vipirin, a coumarin-based HIV-1 Vpr inhibitor, interacts with a hydrophobic region of VPR. J Biol Chem 286, 14049-14056 DOI ScienceOn |
8 | De Clercq E (1992) HIV inhibitors targeted at the reverse transcriptase. AIDS Res Hum Retroviruses 8, 119-134 DOI ScienceOn |
9 | Molla A, Granneman GR, Sun E and Kempf DJ (1998) Recent developments in HIV protease inhibitor therapy. Antiviral Res 39, 1-23 DOI ScienceOn |
10 | Ingale KB and Bhatia MS (2011) HIV-1 integrase inhibitors: a review of their chemical development. Antivir Chem Chemother 22, 95-105 DOI ScienceOn |
11 | Ryser HJ and Flückiger R (2005) Progress in targeting HIV-1 entry. Drug Discov Today 10, 1085-1094 DOI ScienceOn |
12 | Mehellou Y and De Clercq E (2010) Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go? J Med Chem 53, 521-538 DOI ScienceOn |
13 | Flexner C (2007) HIV drug development: the next 25 years. Nat Rev Drug Discov 6, 959-966 DOI ScienceOn |
14 | Condra JH, Schleif WA, Blahy OM et al (1995) In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374, 569-571 DOI ScienceOn |
15 | Freed EO (1998) HIV-1 gag proteins: diverse functions in the virus life cycle. Virology 251, 1-15 DOI ScienceOn |
16 | Domagala JM, Bader JP, Gogliotti RD et al (1997) A new class of anti-HIV-1 agents targeted toward the nucleocapsid protein NCp7: the 2, 2'-dithiobisbenzamides. Bioorg Med Chem 5, 569-579 DOI ScienceOn |